Login to Your Account



Cracking the IPO Window: Who's After Cumberland?

By Trista Morrison


Wednesday, August 12, 2009
Cumberland Pharmaceuticals Inc. may not be a traditional biotech, but it's still the first drug company to price an initial public offering since Bioheart Inc.'s measly $5.8 million debut 15 months ago. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription